Search results
Results from the WOW.Com Content Network
Zolpidem is a nonbenzodiazepine, or Z-drug, which acts as a sedative and hypnotic. [11][20] Zolpidem is a GABA A receptor agonist of the imidazopyridine class. [11] It works by increasing GABA effects in the central nervous system by binding to GABA A receptors at the same location as benzodiazepines. [11]
Generic Product Identifier. The Generic Product Identifier (GPI) is a 14-character hierarchical classification system created by Wolters Kluwer's Medi-Span that identifies drugs from their primary therapeutic use down to the unique interchangeable product regardless of manufacturer or package size. The code consists of seven subsets, each ...
Hydrochlorothiazide. Hydrochlorothiazide, sold under the brand name Hydrodiuril among others, is a diuretic medication used to treat hypertension and swelling due to fluid build-up. [4] Other uses include treating diabetes insipidus and renal tubular acidosis and to decrease the risk of kidney stones in those with a high calcium level in the ...
Methylphenidate, sold under the brand names Ritalin (/ ˈrɪtəlɪn / RIT-ə-lin) and Concerta (/ kənˈsɜːrtə / kən-SUR-tə) among others, is a central nervous system (CNS) stimulant used medically to treat attention deficit hyperactivity disorder (ADHD) and, to a lesser extent, narcolepsy.
Vilazodone. Vilazodone, sold under the brand name Viibryd among others, is a medication used to treat major depressive disorder. [1] It is classified as a serotonin modulator [1] and is taken by mouth. [1] Common side effects include nausea, diarrhea, and trouble sleeping. [1]
Susan Spratt, an endocrinologist and the senior medical director for the Population Health Management Office at Duke Health, went so far as to compare it to a "miracle pill," NBC News reported.
PubMed. PubMed is a free database including primarily the MEDLINE database of references and abstracts on life sciences and biomedical topics. The United States National Library of Medicine (NLM) at the National Institutes of Health maintains the database as part of the Entrez system of information retrieval.
An equivalent two pill regimen is available in developing countries at a price of about US$1.00 per day, as Gilead Sciences has licensed the patents covering emtricitabine/tenofovir to the Medicines Patent Pool [16] and Merck and Co makes efavirenz available in developing countries at a reduced price. [17]